CHCT Stock Analysis: Community Healthcare Trust | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 509m USD | 12M Return: 30.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.61M
Qual. Beats: 0
Rev. Trend: 94.2%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Community Healthcare Trust Incorporated (NYSE: CHCT) is a real estate investment trust (REIT) based in Franklin, Tennessee, that owns income-producing real estate properties leased to operators of outpatient healthcare services across the United States. Founded on March 28, 2014, the company was established to focus on healthcare-related real estate in targeted sub-markets throughout the country.
As of March 31, 2026, the company reported total investments of approximately $1.2 billion across 198 real estate properties located in 36 states, encompassing roughly 4.5 million square feet of leasable space. CHCT trades as a small-cap stock and is classified within the Health Care REITs sub-industry of the Real Estate sector.
As a REIT, CHCT is generally required to distribute a significant portion of its taxable income to shareholders in the form of dividends, a structure common to publicly traded REITs. Healthcare REITs such as CHCT typically operate on long-term lease agreements with medical providers, generating relatively stable rental income tied to the broader healthcare delivery system.
- Outpatient rental income grows on property acquisitions and escalators
- Higher interest rates pressure AFFO and dividend coverage
- Medicare and Medicaid reimbursement cuts weaken tenant credit quality
| Net Income: 6.06m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.50 > 1.0 |
| NWC/Revenue: -195.0% < 20% (prev -151.1%; Δ -43.88% < -1%) |
| CFO/TA 0.06 > 3% & CFO 55.8m > Net Income 6.06m |
| Net Debt (566.0m) to EBITDA (78.5m): 7.21 < 3 |
| Current Ratio: 0.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (27.0m) vs 12m ago 0.97% < -2% |
| Gross Margin: 62.80% > 18% (prev 70.77%; Δ -7.97% > 0.5%) |
| Asset Turnover: 12.27% > 50% (prev 11.83%; Δ 0.44% > 0%) |
| Interest Coverage Ratio: 1.21 > 6 (EBIT TTM 35.1m / Interest Expense TTM 29.0m) |
| A: -0.24 (Total Current Assets 40.3m - Total Current Liabilities 279.0m) / Total Assets 1.01b |
| B: -0.30 (Retained Earnings -306.2m / Total Assets 1.01b) |
| C: 0.04 (EBIT TTM 35.1m / Avg Total Assets 997.6m) |
| D: 0.72 (Book Value of Equity 421.3m / Total Liabilities 588.8m) |
| Altman-Z'' = -1.55 = D |
| DSRI: 0.68 (Receivables 37.7m/53.1m, Revenue 122.4m/116.5m) |
| GMI: 1.13 (GM 70.77% / 62.80%) |
| AQI: 1.03 (AQ_t 0.96 / AQ_t-1 0.93) |
| SGI: 1.05 (Revenue 122.4m / 116.5m) |
| TATA: -0.05 (NI 6.06m - CFO 55.8m) / TA 1.01b) |
| Beneish M = -3.13 (Cap -4..+1) = AA |
As of July 18, 2026, the stock is trading at USD 18.81 with a total of 228,697 shares traded. Over the past week, the price has changed by +4.44%, over one month by +7.86%, over three months by +9.69% and over the past year by +30.35%.
Current recommended Stop Loss: 18.20 (which is 3.2% or 1.5 ATR below the current price).
Community Healthcare Trust has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CHCT.
- StrongBuy: 2
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 18.8 | -0.3% |
P/E Trailing = 148.3333
P/E Forward = 37.3134
P/S = 4.1213
P/B = 1.2253
Revenue TTM = 122.4m USD
EBIT TTM = 35.1m USD
EBITDA TTM = 78.5m USD
Long Term Debt = 274.3m USD (from longTermDebt, last quarter)
Short Term Debt = 148k USD (from shortTermDebt, last quarter)
Debt = 568.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 3.99m
Net Debt = 566.0m USD (calculated: Debt 568.7m - CCE 2.62m)
Enterprise Value = 1.07b USD (508.6m + Debt 568.7m - CCE 2.62m)
Interest Coverage Ratio = 1.21 (Ebit TTM 35.1m / Interest Expense TTM 29.0m)
EV/FCF = 34.65x (Enterprise Value 1.07b / FCF TTM 31.0m)
FCF Yield = 2.89% (FCF TTM 31.0m / Enterprise Value 1.07b)
FCF Margin = 25.34% (FCF TTM 31.0m / Revenue TTM 122.4m)
Net Margin = 4.95% (Net Income TTM 6.06m / Revenue TTM 122.4m)
Gross Margin = 62.80% ((Revenue TTM 122.4m - Cost of Revenue TTM 45.5m) / Revenue TTM)
Gross Margin QoQ = 79.80% (prev 10.68%)
Tobins Q-Ratio = 1.06 (Enterprise Value 1.07b / Total Assets 1.01b)
Interest Expense / Debt = 5.10% (Interest Expense 29.0m / Debt 568.7m)
Taxrate = 0.45% (23.0k / 5.12m)
NOPAT = 34.9m (EBIT 35.1m * (1 - 0.45%))
Current Ratio = 0.14 (Total Current Assets 40.3m / Total Current Liabilities 293.9m)
Debt / Equity = 1.35 (Debt 568.7m / totalStockholderEquity, last quarter 421.3m)
Debt / EBITDA = 7.21 (Net Debt 566.0m / EBITDA 78.5m)
Debt / FCF = 18.25 (Net Debt 566.0m / FCF TTM 31.0m)
Total Stockholder Equity = 428.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.61% (Net Income 6.06m / Total Assets 1.01b)
RoE = 1.41% (Net Income TTM 6.06m / Total Stockholder Equity 428.8m)
RoCE = 4.99% (EBIT 35.1m / Capital Employed (Equity 428.8m + L.T.Debt 274.3m))
RoIC = 3.47% (NOPAT 34.9m / Invested Capital 1.01b)
WACC = 5.97% (E(508.6m)/V(1.08b) * Re(6.97%) + D(568.7m)/V(1.08b) * Rd(5.10%) * (1-Tc(0.00)))
Discount Rate = 6.97% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.94 | Cagr: 1.71%
[DCF] Terminal Value 77.97% ; FCFF base≈28.7m ; Y1≈32.9m ; Y5≈48.5m
[DCF] Fair Price = 5.72 (EV 729.5m - Net Debt 566.0m = Equity 163.5m / Shares 28.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.10 | # QB: 0
Revenue Correlation: 94.21 | Revenue CAGR: 4.53% | SUE: 0.32 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+0.0% | GrowthRev=+5.7%
EPS next Year (2027-12-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+0.0% | GrowthRev=+5.8%